Xgeva Comes Up Short On Clinical Benefit, Has Too Much Risk, ODAC Tells FDA

The oncologic drugs panel rejects an expanded indication for Amgen’s denosumab, saying a 4.2-month delay in progression of bone metastasis in castrate-resistant prostate cancer patients does not offset the risk of osteonecrosis of the jaw.